DMC Group LLC Increases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

DMC Group LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 13.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,902 shares of the company’s stock after purchasing an additional 690 shares during the period. DMC Group LLC’s holdings in Moderna were worth $717,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MRNA. Toronto Dominion Bank lifted its holdings in Moderna by 7.8% in the first quarter. Toronto Dominion Bank now owns 164,741 shares of the company’s stock valued at $25,288,000 after acquiring an additional 11,927 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Moderna by 9.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,559,954 shares of the company’s stock worth $393,025,000 after purchasing an additional 210,985 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Moderna by 43.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 39,515 shares of the company’s stock worth $6,069,000 after purchasing an additional 11,876 shares during the last quarter. Csenge Advisory Group raised its holdings in Moderna by 57.9% in the 1st quarter. Csenge Advisory Group now owns 1,858 shares of the company’s stock valued at $285,000 after buying an additional 681 shares during the period. Finally, Ascendant Capital Management LLC acquired a new position in Moderna in the fourth quarter valued at about $359,000. 64.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Jefferies Financial Group dropped their price target on shares of Moderna from $275.00 to $175.00 in a research report on Friday, August 4th. Royal Bank of Canada cut their target price on Moderna from $200.00 to $190.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. UBS Group upgraded Moderna from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $221.00 to $191.00 in a research report on Monday, June 26th. HSBC initiated coverage on shares of Moderna in a research note on Friday, July 14th. They set a “reduce” rating and a $97.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft cut Moderna from a “buy” rating to a “hold” rating and reduced their price objective for the company from $200.00 to $125.00 in a research note on Thursday, August 3rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $155.52.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.99, for a total transaction of $1,694,850.00. Following the completion of the sale, the president now directly owns 1,574,187 shares of the company’s stock, valued at approximately $177,867,389.13. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $112.99, for a total value of $1,694,850.00. Following the transaction, the president now owns 1,574,187 shares of the company’s stock, valued at $177,867,389.13. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Stephane Bancel sold 27,155 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $121.63, for a total value of $3,302,862.65. Following the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $658,254,991.98. The disclosure for this sale can be found here. Insiders have sold a total of 289,209 shares of company stock valued at $33,877,911 over the last quarter. 15.70% of the stock is currently owned by insiders.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $2.78 during trading hours on Tuesday, reaching $106.92. The stock had a trading volume of 2,420,140 shares, compared to its average volume of 3,621,608. The firm has a 50-day moving average of $112.49 and a 200-day moving average of $127.70. The firm has a market cap of $40.69 billion, a price-to-earnings ratio of 38.43 and a beta of 1.63. The company has a current ratio of 3.39, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a fifty-two week low of $95.02 and a fifty-two week high of $217.25.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($3.62) earnings per share for the quarter, beating the consensus estimate of ($3.84) by $0.22. The business had revenue of $344.00 million during the quarter, compared to the consensus estimate of $307.67 million. Moderna had a return on equity of 6.62% and a net margin of 11.33%. The company’s revenue was down 92.8% compared to the same quarter last year. During the same period in the prior year, the company earned $5.24 earnings per share. Equities research analysts predict that Moderna, Inc. will post -4.32 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.